
About this episode
Craig Venter recently passed away at the age of 79 from complications following a cancer diagnosis. He was well known in both science and industry and was an integral part of sequencing the human genome in the late 90s, competing with the government organized Human Genome Project. Through his career, he made many other important contributions in microbiology, with the “minimal cell”, in synthetic biology, and in personalized medicine. GEN editors share anecdotes of their experiences with him, reflect on the impact that his work has had on various fields in biology, in biotech, and in how the world has responded to the disruptions caused by Venter.
Join GEN editors Corinna Singleman, PhD, John Sterling, Kevin Davies, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.
Listed below are links to the GEN stories referenced in this episode of Touching Base:
Genomics Pioneer and Life Sciences Entrepreneur J. Craig Venter Dies at 79
GEN, April 30, 2026
J. Craig Venter Describes a Human Genomics Revolution Still In Progress
By J. Craig Venter, PhD, GEN, June 13, 2025
By Hana El-Samad, PhD, GEN, August 21, 2023
From Sequencing to Sailing: Three Decades of Adventure with Craig Venter
By Fay Lin, PhD, GEN, March 8, 2023
By Kevin Davies, PhD
Hosted by Corinna Singleman, PhD
Hosted by Jonathan D. Grinstein, PhD
Hosted on Acast. See acast.com/privacy for more information.
Get every episode summarized
Each time Touching Base publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Touching Base

BMS’s New Facility, Recursion–Genentech Partnership, Long-COVID and Persistent C...
Touching Base

Axiom’s Hong Kong Bet, Latigo’s Positive Phase II, and Base Editors for Huntingt...
Touching Base

Parkinson’s in the Clinic, Insilico enters Phase III, Vertex Acquires Crinetics
Touching Base

Merck and Insilico Make Deals, Claude Science’s Debut, Vaccines for Neglected Di...
Touching Base